Two more SGLT2 inhibitors recommended in Japan
This article was originally published in Scrip
Executive Summary
Japan has recommended the approval of another two sodium glucose co-transporter 2 (SGLT2) inhibitor drugs for type 2 diabetes, Taisho's luseogliflozin and Sanofi/Kowa's tofogliflozin (licensed from Chugai), setting the stage for a major marketing battle later this year.